CRISPR-based RNA editing: diagnostic applications and therapeutic options

被引：10
作者：
Gulei, Diana [1 ]
Raduly, Lajos [2 ,3 ]
Berindan-Neagoe, Ioana [1 ,2 ,4 ]
Calin, George Adrian [5 ,6 ]
机构：
[1] Univ Med & Pharm Iuliu Hatieganu, MedFuture Res Ctr Adv Med, Cluj Napoca, Romania
[2] Univ Med & Pharm Iuliu Hatieganu, Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca, Romania
[3] Univ Agr Sci & Vet Med, Dept Pathophysiol, Cluj Napoca, Romania
[4] Oncol Inst Prof Dr Ion Chiricuta, Dept Funct Genom & Expt Pathol, Cluj Napoca, Romania
[5] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Ctr RNA Inference & Noncoding RNAs, Houston, TX 77030 USA
来源：
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2019年 / 19卷 / 02期
基金：
美国国家卫生研究院;
关键词：
DNA/RNA editing; diagnostic; non-coding RNA; programmable nucleases; therapy; GENE-THERAPY; NONCODING RNAS; MUTATIONS; MICRORNAS; EFFICIENT; TARGETS; GUIDE;
D O I：
10.1080/14737159.2019.1568242
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：83 / 88
页数：6
相关论文
共 51 条
  • [1] Site-directed RNA editing by adenosine deaminase acting on RNA for correction of the genetic code in gene therapy
    Azad, Md T. A.
    Bhakta, S.
    Tsukahara, T.
    [J]. GENE THERAPY, 2017, 24 (12) : 779 - 786
  • [2] Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
    Bennett, Jean
    Wellman, Jennifer
    Marshall, Kathleen A.
    McCague, Sarah
    Ashtari, Manzar
    DiStefano-Pappas, Julie
    Elci, Okan U.
    Chung, Daniel C.
    Sun, Junwei
    Wright, J. Fraser
    Cross, Dominique R.
    Aravand, Puya
    Cyckowski, Laura L.
    Bennicelli, Jeannette L.
    Mingozzi, Federico
    Auricchio, Alberto
    Pierce, Eric A.
    Ruggiero, Jason
    Leroy, Bart P.
    Simonelli, Francesca
    High, Katherine A.
    Maguire, Albert M.
    [J]. LANCET, 2016, 388 (10045) : 661 - 672
  • [3] Molecular Pathways: microRNAs, Cancer Cells, and Microenvironment
    Berindan-Neagoe, Ioana
    Calin, George A.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6247 - 6253
  • [4] RNA editing of human microRNAs
    Blow, Matthew J.
    Grocock, Russell J.
    van Dongen, Stijn
    Enright, Anton J.
    Dicks, Ed
    Futreal, P. Andrew
    Wooster, Richard
    Stratton, Michael R.
    [J]. GENOME BIOLOGY, 2006, 7 (04)
  • [5] BOLSCHER BGJM, 1991, BLOOD, V77, P2482
  • [6] Braicu C, 2013, CURR MED CHEM, V20, P3561
  • [7] Bullock Marc D., 2015, Non-Coding RNA, V1, P53, DOI 10.3390/ncrna1010053
  • [8] Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance
    Calin, GA
    Croce, CM
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (02) : 167 - 173
  • [9] CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
    Chen, Janice S.
    Ma, Enbo
    Harrington, Lucas B.
    Da Costa, Maria
    Tian, Xinran
    Palefsky, Joel M.
    Doudna, Jennifer A.
    [J]. SCIENCE, 2018, 360 (6387) : 436 - +
  • [10] Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9
    Chira, Sergiu
    Gulei, Diana
    Hajitou, Amin
    Berindan-Neagoe, Ioana
    [J]. TRENDS IN BIOTECHNOLOGY, 2018, 36 (07) : 653 - 660
123456